A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a first in human(FIH) study to characterize the safety, tolerability,
pharmacokinetics (PK), immunogenicity and anti-tumor activity of AK109, an anti-VEGFR2
monoclonal antibody, as a single agent in adult subjects with advanced solid tumor.